Press release
Ineffective Esophageal Motility Treatment Market is Predicted to Reach at a CAGR of 6.1% by 2034
Ineffective Esophageal Motility Treatment Market
Key trends influencing this global market include advancements in diagnostic technologies, a shift towards personalized medicine, and innovations in treatment approaches. These factors are driving substantial advancements in the management of ineffective esophageal motility on a global scale.
๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐จ๐ฉ๐ฒ ๐จ๐ ๐๐ก๐ข๐ฌ ๐๐๐ฉ๐จ๐ซ๐ญ:
https://www.factmr.com/connectus/sample?flag=S&rep_id=9612
Country-wise Insights
North America and East Asia are dominant regions in the ineffective esophageal motility treatment market. By 2024, North America is expected to hold 46.5% of the global market share, with a projected CAGR of 6.2% during the forecast period. Meanwhile, East Asia is anticipated to capture 12.1% of the market share in 2024, with a promising CAGR of 7.0% over the forecast period.
Category-wise Insights
Drug-based treatments are preferred by patients due to their ease of administration and high compliance rates. The pharmaceutical industry's continuous research and development efforts, coupled with streamlined regulatory pathways, contribute to the availability of new and improved drugs targeting esophageal motility disorders.
The induced pluripotent stem cell (iPSC) market is poised for significant growth, driven by increased investments in the automation of iPSC production, a rapid therapy product pipeline, and advancements in omics-based data understanding. Tissue engineering and biotechnology companies are also investing in R&D to expand the applications of iPSCs and develop novel stem cell therapies for various diseases.
Read More: https://www.factmr.com/report/ineffective-esophageal-motility-treatment-market
Competitive Landscape
Key players in the ineffective esophageal motility treatment market include Johnson & Johnson, Mylan Pharmaceuticals, Medicus Ltd., Dr. Reddy's Laboratories Ltd., Torax Medical, Medtronic Plc, AstraZeneca Plc, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, GlaxoSmithKline Plc., Bayer AG, Pfizer Inc., Bausch Health Companies Inc., Laborie, Mederi Therapeutics, Inc., Becton, Dickinson and Company, EndoGastric Solutions Inc., Olympus, and Pentax.
Manufacturers focusing on interdisciplinary approaches and care coordination are well-positioned to capitalize on opportunities in this evolving landscape. The rising prevalence of esophageal disorders underscores the importance of addressing this healthcare challenge through innovative treatments aimed at addressing the root causes.
Recent Advancements
In 2021, Ethicon (a subsidiary of Johnson & Johnson) introduced the Echelon+ Stapler, enhancing tissue deformation and staple formation in challenging surgical situations.
At Arab Health 2020, Olympus Medical Systems unveiled the latest Endocyto colonoscope and gastroscope, promising improved diagnostic accuracy and better outcomes for patients with gastrointestinal disorders.
In May 2022, Dr. Reddy's Laboratories announced an exclusive partnership with South Korean-based HK inno.N Corporation for the supply and commercialization of Tegoprazan, approved for treating gastrointestinal illnesses in India and other emerging markets.
Segmentation of the Ineffective Esophageal Motility Treatment Market
By Product Type:
Devices
Drugs
By Indication:
Dysphagia
GERD
Burning Chest Pain
Achalasia
By Product Type:
Institutional Sales
Retail Sales
By Region:
North America
Latin America
Europe
East Asia
South Asia & Oceania
Middle East & Africa
๐๐จ๐ง๐ญ๐๐๐ญ:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com
๐๐๐จ๐ฎ๐ญ ๐ ๐๐๐ญ.๐๐
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Ineffective Esophageal Motility Treatment Market is Predicted to Reach at a CAGR of 6.1% by 2034 here
News-ID: 3563193 • Views: โฆ
More Releases from Fact.MR
Healthcare AR VR Market Dynamics: Influence of Key Players Including Atheer, Aug โฆ
The global healthcare AR VR market is experiencing explosive growth, with its valuation expected to surge from USD 2.8 billion in 2024 to USD 14.85 billion by 2034. This remarkable expansion reflects a compound annual growth rate (CAGR) of 18.2% over the forecast period from 2024 to 2034. The market's momentum is driven by the transformative potential of augmented reality (AR) and virtual reality (VR) in enhancing medical training, surgicalโฆ
Ad-Supported Video on Demand (AVOD) Market to Reach USD 47.84 Billion by 2034, L โฆ
In an era where binge-watching has become a global pastime, the ad-supported video on demand (AVOD) market is poised for unprecedented expansion, according to a groundbreaking new report from Fact.MR. Valued at US$ 40.12 billion in 2024, the sector is projected to skyrocket to US$ 150.8 billion by 2034, achieving a robust compound annual growth rate (CAGR) of 14.2%. This meteoric rise underscores the transformative power of AVOD platforms, whichโฆ
Continuous Positive Airway Pressure (CPAP) Device Market Expanding at 5.45% CAGR โฆ
The global continuous positive airway pressure (CPAP) device market is on a steady growth trajectory, with its valuation expected to rise from USD 3,969.5 million in 2024 to USD 7,286.3 million by 2034. This expansion corresponds to a compound annual growth rate (CAGR) of 6.3% over the forecast period from 2024 to 2034. The market's momentum is driven by the increasing prevalence of sleep apnea, growing awareness of sleep disorders,โฆ
Cranio Maxillofacial Fixation Device Market is Projected to Reach USD 6,030 Mill โฆ
The global cranio maxillofacial fixation device market is expected to experience significant growth, with its valuation rising from USD 2,946 million in 2025 to USD 6,030 million by 2035. This expansion corresponds to a compound annual growth rate (CAGR) of 7.4% over the forecast period from 2025 to 2035. The market's momentum is driven by rising concerns over facial trauma and genetic imperfections, increasing demand for minimally invasive surgeries, andโฆ
More Releases for Ineffective
Terischwartz Associates Exposes the True Cost of Ineffective Meetings in Today's โฆ
Image: https://www.abnewswire.com/upload/2025/07/3cd3e20ec6c36670720e5834999ed2ab.jpg
Executives across the country sit in boardrooms and virtual rooms alike, facing a steady stream of meetings that move agendas sideways, not forward. At the center of this epidemic lies a rarely acknowledged truth: most meetings lack a clear purpose, structure, or outcome. Despite their ubiquity, they remain one of the greatest hidden inefficiencies in modern business.
Evan Unger [https://www.terischwartzassociates.com/our-team/evan-unger/], managing partner at a national leadership consulting firm, studies thisโฆ
Steep learning curve and ineffective customer support keep AccountEdge second to โฆ
Brandon, MB--May 25, 2023: AccountEdge helps small businesses establish inventory, billing, managing contacts, creating and tracking sales and purchases. It's compatible with both Mac and Windows operating systems. An on-premise and accounting management solution, it gives users the freedom to create an eCommerce platform where they can sell items online using Shopify, download orders directly to the account and synchronize the inventory items for selling. The banking tool givesโฆ
Ineffective Esophageal Motility Treatment Market 2022 Global Market Analysis and โฆ
Ineffective esophageal motility treatment leads to a reduction in muscle damage and improved outcomes, improving quality of life and resulting in long-term benefits. Device-based treatment and IEMT drugs have already had a substantial impact on how symptoms of GERD and achalasia are treated.
The first and the most important factor driving the growth of the ineffective esophageal motility treatment market is the increasing prevalence of gastroesophageal reflux disease. Other factors, suchโฆ
The Ineffective Esophageal Motility Treatment Market to keep pace with the lates โฆ
The Ineffective Esophageal Motility Treatment Market is expected to witness a staggering CAGR going forward. The gamut of care is being driven by the usage of sensors, digital technologies, and wearables, thereby allowing the healthcare personnel to delve deep into the patientsโ live โ be it pre-operative, post-operative, or the period in between. Consumer tech companies are into making caregivers visible outside of the clinical environment a reality.
Ineffective esophagealโฆ
The Ineffective Esophageal Motility Treatment Market to Adopt Digitization
The Ineffective Esophageal Motility Treatment Market is there to witness remarkable growth in the forecast period. The existing scenario implies the consumerization of healthcare. In other words, technology is relieving the hospital staff from providing an appropriate level of the care needed, that too, in a better way. Data-driven diagnosis has seen the light of the day in wake of habits and requirements of smartphone-oriented patients. This would be theโฆ
IAS Questions MoH Push for Ineffective Vaccine
The Immunisation Awareness Society is raising concern about the inadequate level of information provided to the public regarding the whooping cough vaccine.
Auckland, New Zealand, April 11, 2012 -- GIVEN the current push by the Ministry of Health (MoH) for people to get their whooping cough (pertussis) vaccinations, the Immunisation Awareness Society (IAS) is raising concerns about the inadequate level of information provided around vaccination in New Zealand.
The latest figures fromโฆ
